Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

6.890 -0.410 (-5.62%)
Streaming Delayed Price Updated: 2:44 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
The 3 Best Gene Editing Stocks to Buy in July 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. 
Via InvestorPlace
3 Pharma Stocks Already Ushering in the Next Biotech Boom
So long as diseases afflict the human condition, there will likely always be a need for pharma stocks. Here are three to consider. 
Via InvestorPlace
The 3 Best Biotech Stocks to Buy in July 2024
For investors looking for promising biotech investments should explore the best biotech stocks to watch in July 2024. 
Via InvestorPlace
Cathie Wood's Ark Invest Dumps Another $3.25M Worth Of Tesla Shares Amid Searing Q2 Deliveries Rally
Via Benzinga
Cathie Wood's Ark Invest Sells Tesla Shares Worth $14.5M Amid Rally Driven By Q2 Delivery Numbers, Picks Up Palantir Shares Again Today
Via Benzinga
Unveiling 6 Analyst Insights On Intellia Therapeutics
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Intellia Therapeutics
Via Benzinga
3 Stocks Cathie Wood Just Bought to Get Back on Track in the Second Half of 2024
The popular growth investor is making big moves in July to bounce back after a rough start this year. 
Via The Motley Fool
Treasure Hunt: 3 Biotech Stocks Wall Street Hasn’t Discovered Yet
Undiscovered biotech stocks can be risky but rewarding, especially when it involves mid-cap stocks with promise and no profit. 
Via InvestorPlace
You’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.
The best gene editing stocks to buy are those with strong tehnogical applications and genuine commercialization prospects. 
Via InvestorPlace
Cathie Wood's Ark Invest Acquires $7.3M Worth Of Shares In This Promising Netflix Competitor, Sells Off Coinbase Stock Amid Bitcoin Slump
On Wednesday, Cathie Wood-led Ark Invest made significant trades in Roku Inc (NASDAQ:ROKU) and Coinbase Global Inc (NASDAQ:COIN), amidst a volatile market. 
Via Benzinga
3 Gene Editing Stocks That Could Make Your Grandchildren Rich
Explore gene-editing stocks with long-term growth potential, offering innovative solutions to previously untreatable conditions. 
Via InvestorPlace
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach. 
Via Benzinga
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for June 2024
Investors looking for companies with high growth potential should consider investing in these three strong buy Cathie Wood stocks. 
Via InvestorPlace
Avidity Biosciences And CleanSpark Were Among The 10 Biggest Mid-Cap Stock Gainers Last Week (June 9-June 15): Are These In Your Portfolio?
Top mid-cap performers: Avidity Biosciences, Iris Energy, Hims & Hers Health, John Wiley & Sons, Element Solutions, CleanSpark, Enovix Corp, Axcelis Tech, Intellia Therapeutics, Korn Ferry. 
Via Benzinga
Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness
On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). This decision came amidst a period of market fluctuations and followed a... 
Via Benzinga
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
These companies could generate explosive growth over time. 
Via The Motley Fool
These 2 Words Are Why Intellia Therapeutics Could Be a Smart Buy Right Now
Neither word has anything to do with money -- at least not yet. 
Via The Motley Fool
Cathie Wood-Led Ark Invest Buys $9.9M Worth Of Amazon Shares, Also Picks Up Reddit Stock
Via Benzinga
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The widely followed growth investor made big moves as May came to a close. 
Via The Motley Fool
The 3 Best Biotech Stocks to Buy in June 2024
Explore the best biotech stocks to buy in June 2024, with insights on Protagonist, BridgeBio and Intellia. 
Via InvestorPlace
Cathie Wood Is Buying the Dip on These 2 Biotech Stocks. Should You?
In keeping with Cathie Wood's style, these picks are riskier than average. 
Via The Motley Fool
Why Intellia Therapeutics Shares Are Trading Higher Monday
Intellia's NTLA-2002 is an experimental CRISPR based gene-editing therapy being developed as a one-time treatment for hereditary angioedema (HAE). The company announced the single does treatment led to... 
Via Benzinga
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
Cathie Wood-Led Ark Invest Sells Nearly $28M Worth Of Robinhood Shares Amid Crypto API Launch And Lackluster Bitcoin Price Action
On Thursday, Cathie Wood-led Ark Invest made notable adjustments to its portfolio, including a significant sell-off of Robinhood Markets Inc (NASDAQ:HOOD) shares. 
Via Benzinga
Cathie Wood's Ark Innovation ETF Sees Sharp Decline Among Top Holdings — Here Are 10-Largest Losers Within ARKF
Cathie Wood's flagship ARK Innovation ETF has been navigating through significant losses, showcasing the challenges faced by some of its major holdings. 
Via Benzinga
Topics ETFs
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular growth investor keeps adding to some of her favorite falling stocks. 
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular growth investor bought into one of Thursday's biggest losers and two stocks that have fallen sharply over the past year. 
Via The Motley Fool
NTLA Stock Earnings: Intellia Therapeutics Beats EPS, Beats Revenue for Q1 2024
NTLA stock results show that Intellia Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.